News
FDA Officials Say We Will Need COVID Jabs In The Future
According to a trio of prominent US Food and Drug Administration experts, the US may need to update its COVID-19 vaccines every year, and "a new normal" may comprise a yearly vaccine alongside a seasonal flu shot.
The advent of...
News
Moderna Fine Tweaks Its Booster Prior To The Fall Season
The question is whether to boost or not to boost. The answer is a resounding yes, as per officials at mRNA expert Moderna. Moderna's chief medical officer, Paul Burton, M.D., Ph.D., stated that the SARS-CoV-2 omicron variant's meteoric rise...
News
Astorg to acquire leading Pharmaceutical Contract Development & Manufacturing Organization CordenPharma from ICIG
Astorg and International Chemical Investors Group announce that they have signed a binding agreement whereby Astorg will acquire CordenPharma (โCordenPharmaโ or the โCompanyโ), a global leading pharmaceutical CDMO (Contract Development & Manufacturing Organisation) with highly differentiated capabilities in Active...
Industry Reports
Amid Global Setbacks, Indian Pharma Exports Grow In 2021-22
The Government of India recentlyย announced that the pharmaceutical sector had its best-ever export performance in 2021-22, with a phenomenal increase of about $10 billion in just eight years. Since 2013-14, the country's pharmaceutical sector has grown by 103%, from...
Industry Reports
Samsung Biologics Reports First Quarter 2022 Financial Results
Samsung Biologics, the worldโs leading contract development and manufacturing organization, announced strong financial results for the first quarter of fiscal year 2022.
John Rim, CEO of Samsung Biologics, stated, โSamsung Biologicsโ strong start to the 2022 fiscal year was driven...
News
Omicron Variant Descendants Begin Their Own Coronavirus Wave
The data is undeniable: COVID-19 instances and hospitalizations are on the rise in the United States, despite patchy documentation. Most states are witnessingย an upsurge, with Washington, Georgia, Mississippi,ย South Dakota, Nevada, Maine, Hawaii,ย and Montana seeing more than a 50% rise...
News
Pfizer Holding To $22B Paxlovid Sales Plan Amid Slow Sales
Pfizer officials stated on an earnings callย that while Paxlovid's first-quarter sales may seem to be low, there will be plenty more revenues in the next three months. Paxlovid, Big Pharma's COVID-19 oral antiviral, may soon benefit from agreements in...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read
















